HK1211865A1 - Nootropic compositions for improving memory performance - Google Patents
Nootropic compositions for improving memory performanceInfo
- Publication number
- HK1211865A1 HK1211865A1 HK15112901.6A HK15112901A HK1211865A1 HK 1211865 A1 HK1211865 A1 HK 1211865A1 HK 15112901 A HK15112901 A HK 15112901A HK 1211865 A1 HK1211865 A1 HK 1211865A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- memory performance
- improving memory
- nootropic
- compositions
- nootropic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696961P | 2012-09-05 | 2012-09-05 | |
| EP12306062.6A EP2705841A1 (fr) | 2012-09-05 | 2012-09-05 | Combinaisons des agents nootropiques destinées au traitement des dysfonctionnements cognitifs |
| PCT/EP2013/068302 WO2014037412A1 (fr) | 2012-09-05 | 2013-09-04 | Compositions nootropiques pour améliorer les performances de mémoire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1211865A1 true HK1211865A1 (en) | 2016-06-03 |
Family
ID=46963635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15112901.6A HK1211865A1 (en) | 2012-09-05 | 2015-12-31 | Nootropic compositions for improving memory performance |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9789098B2 (fr) |
| EP (3) | EP2705841A1 (fr) |
| JP (1) | JP6228212B2 (fr) |
| KR (1) | KR20150067168A (fr) |
| CN (2) | CN108578396A (fr) |
| AU (1) | AU2013311735B2 (fr) |
| BR (1) | BR112015004843A2 (fr) |
| CA (2) | CA2883691C (fr) |
| EA (1) | EA030385B1 (fr) |
| ES (2) | ES2886873T3 (fr) |
| HK (1) | HK1211865A1 (fr) |
| IL (1) | IL237438A0 (fr) |
| MX (1) | MX2015002796A (fr) |
| NZ (1) | NZ705917A (fr) |
| SG (1) | SG11201501634VA (fr) |
| WO (1) | WO2014037412A1 (fr) |
| ZA (1) | ZA201501812B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| EP3104850A1 (fr) | 2014-02-11 | 2016-12-21 | Pharnext | Combinaison de baclofène, d'acamprosate et de triglycérides à chaîne moyenne pour le traitement de troubles neurologiques |
| JP6930969B2 (ja) * | 2015-07-08 | 2021-09-01 | ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
| US10603297B2 (en) * | 2017-10-04 | 2020-03-31 | Harald Murck | Treatment for therapy refractory depression |
| US20210236445A1 (en) * | 2018-01-29 | 2021-08-05 | Pharnext | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| EP4281056A1 (fr) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Stratégie de combinaison de médicaments pour le traitement des troubles psychiatriques et neurologiques dans lesquels il existe une anhédonie ou un dysfonctionnement lié à la motivation |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| KR101140559B1 (ko) | 2003-08-20 | 2012-07-05 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
| EP1716115B1 (fr) | 2003-12-30 | 2013-02-27 | XenoPort, Inc. | Synthese de promedicaments a base de carbamate d'acyloxyalkyle et leurs intermediaires |
| EP2117517B1 (fr) | 2007-01-11 | 2011-06-01 | XenoPort, Inc. | Formes galéniques orales à libération prolongée d'un promédicament de r-baclofène et procédés de traitement |
| WO2009033079A1 (fr) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Promédicaments de libération de cyclisation d'ester de néopentyle sulfonyle d'ester d'acide pantoïque masqués extérieurement, leurs compositions et procédés d'utilisation |
| US8168617B2 (en) | 2007-09-07 | 2012-05-01 | Xenoport, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200932734A (en) | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009061934A1 (fr) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Utilisation de promédicaments d'agonistes de gaba b pour le traitement de douleur neuropathique et musculo-squelettique |
| WO2009070583A1 (fr) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, leur procédé de préparation, et leur utilisation en tant qu'inhibiteurs de phosphodiestérase 10 |
| US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| WO2009096985A1 (fr) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Formes posologiques orales particulaires à libération soustenue de promédicaments de (r)-baclofène et procédés de traitement correspondants |
| DK2282778T3 (en) * | 2008-04-29 | 2017-05-01 | Pharnext | NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC |
| NZ589304A (en) * | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| NZ594648A (en) | 2009-03-03 | 2013-12-20 | Xenoport Inc | Sustained release oral dosage forms of an r-baclofen prodrug |
| JP2012524065A (ja) | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体 |
| WO2010138833A1 (fr) * | 2009-05-29 | 2010-12-02 | Wyeth | Imidazo[1,5-a]quinoxalines substituées en tant qu'inhibiteurs de la phosphodiestérase 10 |
| EP2322163A1 (fr) * | 2009-11-03 | 2011-05-18 | Pharnext | Nouvelles approches thérapeutiques pour traiter la maladie d'Alzheimer |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20120016021A1 (en) * | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| EP2705842A1 (fr) * | 2012-09-05 | 2014-03-12 | Pharnext | Approches thérapeutiques pour le traitement de la maladie de Parkinson |
| SI2796132T1 (sl) * | 2011-03-01 | 2018-09-28 | Pharnext | Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат |
-
2012
- 2012-09-05 EP EP12306062.6A patent/EP2705841A1/fr not_active Withdrawn
-
2013
- 2013-09-04 CA CA2883691A patent/CA2883691C/fr active Active
- 2013-09-04 CN CN201810311698.7A patent/CN108578396A/zh active Pending
- 2013-09-04 EP EP13759490.9A patent/EP2892519B1/fr active Active
- 2013-09-04 WO PCT/EP2013/068302 patent/WO2014037412A1/fr active Application Filing
- 2013-09-04 NZ NZ705917A patent/NZ705917A/en not_active IP Right Cessation
- 2013-09-04 KR KR1020157008675A patent/KR20150067168A/ko not_active Application Discontinuation
- 2013-09-04 EA EA201500294A patent/EA030385B1/ru not_active IP Right Cessation
- 2013-09-04 BR BR112015004843A patent/BR112015004843A2/pt not_active Application Discontinuation
- 2013-09-04 CA CA3092974A patent/CA3092974A1/fr not_active Abandoned
- 2013-09-04 US US14/425,987 patent/US9789098B2/en active Active
- 2013-09-04 JP JP2015530379A patent/JP6228212B2/ja active Active
- 2013-09-04 SG SG11201501634VA patent/SG11201501634VA/en unknown
- 2013-09-04 ES ES18196160T patent/ES2886873T3/es active Active
- 2013-09-04 MX MX2015002796A patent/MX2015002796A/es unknown
- 2013-09-04 EP EP18196160.8A patent/EP3443955B1/fr active Active
- 2013-09-04 ES ES13759490T patent/ES2709874T3/es active Active
- 2013-09-04 CN CN201380052487.1A patent/CN104884053B/zh active Active
- 2013-09-04 AU AU2013311735A patent/AU2013311735B2/en not_active Ceased
-
2015
- 2015-02-26 IL IL237438A patent/IL237438A0/en unknown
- 2015-03-17 ZA ZA2015/01812A patent/ZA201501812B/en unknown
- 2015-12-31 HK HK15112901.6A patent/HK1211865A1/xx unknown
-
2017
- 2017-10-13 US US15/783,380 patent/US10265304B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2883691C (fr) | 2020-11-10 |
| CA2883691A1 (fr) | 2014-03-13 |
| CN104884053A (zh) | 2015-09-02 |
| EA201500294A1 (ru) | 2015-09-30 |
| CN108578396A (zh) | 2018-09-28 |
| NZ705917A (en) | 2018-02-23 |
| US10265304B2 (en) | 2019-04-23 |
| ES2709874T3 (es) | 2019-04-22 |
| ZA201501812B (en) | 2016-07-27 |
| AU2013311735A1 (en) | 2015-04-02 |
| US20150224092A1 (en) | 2015-08-13 |
| EP2705841A1 (fr) | 2014-03-12 |
| KR20150067168A (ko) | 2015-06-17 |
| JP2015527380A (ja) | 2015-09-17 |
| CN104884053B (zh) | 2018-05-04 |
| EA030385B1 (ru) | 2018-07-31 |
| CA3092974A1 (fr) | 2014-03-13 |
| JP6228212B2 (ja) | 2017-11-08 |
| WO2014037412A1 (fr) | 2014-03-13 |
| EP2892519A1 (fr) | 2015-07-15 |
| ES2886873T3 (es) | 2021-12-21 |
| EP3443955B1 (fr) | 2021-06-16 |
| AU2013311735B2 (en) | 2018-02-01 |
| SG11201501634VA (en) | 2015-04-29 |
| IL237438A0 (en) | 2015-04-30 |
| EP2892519B1 (fr) | 2018-11-07 |
| US9789098B2 (en) | 2017-10-17 |
| BR112015004843A2 (pt) | 2017-07-04 |
| EP3443955A1 (fr) | 2019-02-20 |
| MX2015002796A (es) | 2015-08-20 |
| US20180092890A1 (en) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1211865A1 (en) | Nootropic compositions for improving memory performance | |
| HK1215165A1 (zh) | 組合物 | |
| HK1210019A1 (en) | Chitosan-derived compositions | |
| HK1208354A1 (en) | Compositions | |
| EP2763756A4 (fr) | Compositions à base de bromofluorocarbone | |
| ZA201503157B (en) | Compositions | |
| GB201210800D0 (en) | Compositions | |
| GB201209244D0 (en) | Compositions | |
| GB201201287D0 (en) | Compositions | |
| GB201103942D0 (en) | Compositions | |
| ZA201503062B (en) | Compositions | |
| GB201220068D0 (en) | Compositions | |
| ZA201502542B (en) | Compositions | |
| ZA201406753B (en) | Long acting compositions | |
| GB201219962D0 (en) | Compositions | |
| GB201219973D0 (en) | Compositions | |
| GB201219980D0 (en) | Compositions | |
| TWI561248B (en) | Peracid-generating compositions | |
| EP2926813A4 (fr) | Compositions de métformine-orlistat | |
| GB201223148D0 (en) | Compositions | |
| GB201222702D0 (en) | Compositions | |
| GB201218959D0 (en) | Compositions | |
| GB201209189D0 (en) | Compositions | |
| GB201209187D0 (en) | Compositions | |
| GB201204103D0 (en) | Compositions |